Publicaciones en colaboración con investigadores/as de Instituto Ramón y Cajal de Investigación Sanitaria (8)

2021

  1. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease

    European Journal of Pharmacology, Vol. 895

2018

  1. Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: Possible involvement of different binding sites at the PPARγ receptor

    Journal of Neuroinflammation, Vol. 15, Núm. 1

2017

  1. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2receptor ligands with antagonist/inverse agonist properties

    European Journal of Medicinal Chemistry, Vol. 112, pp. 66-80

2015

  1. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

2013

  1. Neuroprotective properties of standardized extracts of hypericum perforatum on rotenone model of parkinson's disease

    CNS and Neurological Disorders - Drug Targets, Vol. 12, Núm. 5, pp. 665-679

2011

  1. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease

    British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506